Baxter International (BAX) Scheduled to Post Earnings on Thursday

Baxter International (NYSE:BAX) will be releasing its earnings data before the market opens on Thursday, May 2nd. Analysts expect Baxter International to post earnings of $0.61 per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Baxter International (NYSE:BAX) last posted its earnings results on Thursday, February 8th. The medical instruments supplier reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.86 by $0.02. Baxter International had a net margin of 17.77% and a return on equity of 19.49%. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.81 billion. During the same quarter in the previous year, the firm posted $0.88 EPS. The firm’s revenue was up 3.5% on a year-over-year basis. On average, analysts expect Baxter International to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Baxter International Trading Down 0.7 %

NYSE:BAX opened at $40.37 on Wednesday. The company has a current ratio of 1.48, a quick ratio of 1.04 and a debt-to-equity ratio of 1.31. Baxter International has a 12 month low of $31.01 and a 12 month high of $50.21. The company has a market cap of $20.50 billion, a PE ratio of 7.73, a price-to-earnings-growth ratio of 2.16 and a beta of 0.62. The company has a 50 day simple moving average of $41.78 and a two-hundred day simple moving average of $38.71.

Baxter International Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 1st. Shareholders of record on Friday, March 1st were given a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a yield of 2.87%. The ex-dividend date of this dividend was Thursday, February 29th. Baxter International’s dividend payout ratio (DPR) is presently 22.22%.

Wall Street Analyst Weigh In

BAX has been the subject of a number of recent research reports. JPMorgan Chase & Co. boosted their price objective on shares of Baxter International from $38.00 to $44.00 and gave the company a “neutral” rating in a research report on Friday, February 9th. StockNews.com upgraded shares of Baxter International from a “hold” rating to a “buy” rating in a research note on Friday, January 19th. Bank of America lifted their target price on shares of Baxter International from $42.00 to $45.00 and gave the company a “neutral” rating in a research note on Tuesday, March 5th. Citigroup lifted their target price on shares of Baxter International from $41.00 to $44.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Finally, UBS Group lowered their target price on shares of Baxter International from $40.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 6th. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Baxter International has a consensus rating of “Hold” and a consensus price target of $46.30.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.